Lanreotid Pharmathen (Lanreotide)

Lanreotide mimics the natural hormone somatostatin and binds to somatostatin receptors SSTR2 and SSTR5 on target cells. This binding blocks adenylate cyclase, lowers cAMP levels, and suppresses the release of growth hormone, insulin, glucagon, and other peptide hormones, thereby reducing hormone‑driven tumor activity and related symptoms.

The dosage of Lanreotid Pharmathen is individualized by the prescribing clinician based on the patient’s condition, disease severity, and response to therapy. Healthcare professionals determine the appropriate injection volume, frequency, and any necessary adjustments.

Safety data for lanreotide in pregnancy and lactation are limited. The drug should only be used if the potential therapeutic benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.

Lanreotide is similar to other long‑acting somatostatin analogs such as octreotide, but it is formulated for less frequent subcutaneous dosing and may offer comparable efficacy with a different injection schedule. Choice between agents depends on patient preference, dosing convenience, and individual response assessed by the treating physician.

Lanreotid Pharmathen should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

The medication is given as a subcutaneous injection, typically by a healthcare professional. The injection site is rotated to minimize local reactions, and the dose is administered according to the schedule prescribed by the clinician.

Serious adverse events include gallbladder disease (such as cholelithiasis), acute pancreatitis, and severe hypersensitivity reactions like anaphylaxis. Patients should be monitored for abdominal pain, jaundice, or signs of allergic response, and any concerning symptoms should prompt immediate medical evaluation.

Lanreotide is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with uncontrolled diabetes, active gallbladder disease, or a history of pancreatitis. The medication should be avoided in these situations unless a specialist determines that benefits outweigh the risks.